
Strata Skin Sciences (SSKN) appointed industry veteran Erica Jordan as CEO, effective July 12. Prior to joining Strata, Jordan served as chief commercial officer for Revance Therapeutics. Published first on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SSKN | Strata Skin Sciences | 0.00 | -0.00 | -93.84% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.00 | -93.84% |

Strata Skin Sciences (SSKN) appointed industry veteran Erica Jordan as CEO, effective July 12. Prior to joining Strata, Jordan served as chief commercial officer for Revance Therapeutics. Published first on

Strata Skin Sciences (SSKN) is scheduled to report 4th quarter earnings on 03/24/2026. Regarding Q4 estimates, Wall Street analysts expect Strata Skin Sciences to post earnings of -$0.26 per share.

Strata Skin Sciences (SSKN) announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of

STRATA Skin Sciences (SSKN) announces that Johns Hopkins Dermatology has added the XTRAC 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins’ ability

Strata Skin Sciences (SSKN) highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the Journal

The latest update is out from Strata Skin Sciences ( ($SSKN) ). Strata Skin Sciences, Inc. disclosed that after receiving a Nasdaq deficiency notice on August 22, 2025, for failing

The latest announcement is out from Strata Skin Sciences ( ($SSKN) ). STRATA Skin Sciences posted a new investor presentation outlining its strategic initiatives for expansion and growth in December

Strata Skin Sciences ( ($SSKN) ) has provided an announcement. On December 10, 2025, Strata Skin Sciences held its annual meeting of stockholders, where several key decisions were made. The

STRATA Skin Sciences (SSKN) announces its participation in the 2025 Ibero-Latin American Congress of Dermatology November 19-22, 2025, where it presented its XTRAC excimer laser and TheraclearX acne therapy system.

Strata Skin Sciences (($SSKN)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Strata Skin Sciences presented a mixed
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 14, 2025 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Nov 17, 2026TBA | $589.00 | ― | ― | -0.00 | 0.00 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.